Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD), CEL-SCI (NYSEMKT:CVM), Inovio Pharmaceuticals (NYSEMKT:INO)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares declined 1.14% to $8.65. The company on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -2.87% in last session and finished the day at $8.13. Traded volume was 13.50million shares in the last session and the average volume of the stock remained million shares. The beta of the stock remained 1.42. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) insider ownership is 1.70%.

Just six weeks of Gilead Sciences Inc. (NASDAQ:GILD) hotly anticipated combination pill of ledipasvir and Sovaldi (sofosbuvir), given with or without GS-9669 or GS-9451, cured 95 to 100 percent of people with genotype 1 of hepatitis C virus (HCV) in a small pilot study, MedPage Today reports. Gilead Sciences, Inc. (NASDAQ:GILD) dropped -0.43 percent to $79.58 Friday on volume of 20.47million shares. The intra-day range of the stock was $77.81 to $81.35. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $122.41million.

CEL-SCI Corporation (NYSEMKT:CVM) soared 12.50% after the company announced that its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina. CEL-SCI Corporation (NYSEMKT:CVM)’s stock on Mar 7, 2014 reported a increase of 11.90% to the closing price of $1.41. Its fifty two weeks range is $0.53-$3.09. The total market capitalization recorded $78.88million. The overall volume in the last trading session was 7.41million shares. In its share capital, CVM has 48.22million outstanding shares.

Inovio Pharmaceuticals Inc (NYSEMKT:INO) has reportedly completed the underwritten public offering successfully on Tuesday as the company announced the collection of the total gross proceeds of $63.3 million. On Friday, shares of Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -3.13% to close the day at $3.40. Company return on investment (ROI) is -68.30% and its monthly performance is recorded as 35.46%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) quarterly revenue growth is 61.90%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone